Last reviewed · How we verify
6-month dual anti-platelet therapy
The 6-month dual anti-platelet therapy, marketed by Gangnam Severance Hospital, holds a position in the anti-platelet therapy segment with a key composition patent expiring in 2028. The therapy's key strength lies in its defined duration of treatment, which may offer a competitive advantage in patient compliance and outcomes. The primary risk is the potential for increased competition as the key patent approaches expiration in 2028.
At a glance
| Generic name | 6-month dual anti-platelet therapy |
|---|---|
| Also known as | Aspirin and Clopidogrel |
| Sponsor | Gangnam Severance Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation (NA)
- Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (NA)
- Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis (NA)
- The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole) (PHASE4)
- Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy (NA)
- Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) (PHASE4)
- COBRA SHIELD OCT Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-month dual anti-platelet therapy CI brief — competitive landscape report
- 6-month dual anti-platelet therapy updates RSS · CI watch RSS
- Gangnam Severance Hospital portfolio CI